Traders should monitor progress of the EscharEx Phase III trial and regulatory approvals for the new NexoBrid facility as key near-term catalysts. While cash is strong, continued revenue declines and negative EBITDA suggest ongoing execution risk. The reaffirmed guidance provides some forward hope, but near-term fundamentals are weak.
MDWD drugs
MDWD drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 5 $17.45entry
- T+1 · 9mo ago −2.41%α −1.09% · $17.03
- T+5 · 8mo ago −4.99%α −2.75% · $16.58
- T+20 · 8mo ago −3.67%α +0.12% · $16.81
- T+60 · 6mo ago −20.80%α −32.10% · $13.82
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MediWound reported a decline in Q4 and full-year 2025 revenue, driven by lower development services due to the U.S. government shutdown and reduced product sales to Vericel. Despite higher R&D spending on the EscharEx Phase III trial, the company maintained a strong cash position of $53.6 million and reaffirmed its 2026–2028 revenue guidance. The stock remains speculative, tied to upcoming clinical and regulatory catalysts.
Key Financial Metrics
Key Facts
- Q4 2025 revenue was $1.9 million, down 67% from $5.8 million in Q4 2024
- Full-year 2025 revenue was $17.0 million, down from $20.2 million in 2024
- Net loss for 2025 was $23.9 million, or $2.10 per share, compared to $30.2 million, or $3.03 per share, in 2024
- Cash balance increased to $53.6 million at year-end, up from $43.6 million, due to a $30 million registered direct offering
- Company reaffirmed 2026 revenue guidance of $24–26 million, $32–35 million in 2027, and $50–55 million in 2028
- EscharEx Phase III VALUE trial progressing with enrollment and interim assessment expected by end of 2026
- Expanded NexoBrid manufacturing facility now operational, with sixfold capacity increase; regulatory approvals expected in 2026
Financial Impact
Revenue declined 15.8% YoY to $17.0 million; operating loss widened to $25.3 million from $19.4 million in 2024
Risk Factors
- Revenue heavily impacted by U.S. government budget delays; future development revenue remains uncertain
- EscharEx approval and commercial success are not guaranteed; clinical or regulatory setbacks could significantly impact valuation
- High R&D spend ($14.3M in 2025) continues to drive losses despite lower SG&A
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250013 |
Track record
13 reports on MDWD
5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +8.48% at T+60 after the May 27, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $12.90 Now $13.55 +5.04% settles Nov 20
- Nov 12, 20264d ago 6-K Bearish 6/10 No price data
- Nov 12, 20264d ago Press Release Bearish 6/10 Entry $12.97 Now $13.55 −4.47% settles Nov 19
- Nov 5, 202611d ago 6-K Bearish 6/10 Entry $13.33 to $12.97 Now $13.55 −1.65% ▲ +2.70% +5.99% vs SPY
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $13.33 to $12.97 Now $13.55 −1.65% ▲ +2.70% +5.99% vs SPY
- Nov 3, 202613d ago 424B5 Bearish 5/10 Entry $14.20 to $13.82 Now $13.55 +4.58% ▲ +2.68% +1.76% vs SPY
- Sep 22, 20267w ago Press Release Bullish 4/10 Entry $13.95 to $13.80 Now $13.55 −2.87% ▼ −1.08% +0.11% vs SPY
- Jun 2, 202623w ago Insider Cluster Bullish 4/10 Entry $13.76 to $14.30 Now $13.55 −1.53% ▲ +3.92% +6.89% vs SPY
- May 27, 202624w ago Press Release Bearish 5/10 Entry $14.33 to $13.73 Now $13.55 +5.44% ▲ +4.19% +4.66% vs SPY
- May 7, 202627w ago Press Release Neutral 1/10 Entry $17.27 to $16.25 Now $13.55 −21.54% ▼ −5.91% −7.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers